64 related articles for article (PubMed ID: 16313819)
1. Risk factors for methotrexate resistance in low-risk gestational trophoblastic neoplasia patients (FIGO score 0-4).
Jin T; Zhou Z; Lin M; Yuan S; Xue Y; Yin T; Xu R; Chen B; Zhang J; Sun J; Li X; Hu Y; Chen L; Wang H
Am J Cancer Res; 2024; 14(3):1353-1362. PubMed ID: 38590416
[TBL] [Abstract][Full Text] [Related]
2. Comparing biweekly single-dose actinomycin D with multiday methotrexate therapy for low-risk gestational trophoblastic neoplasia (FIGO Score 0-4): study protocol for a prospective, multicentre, randomized trial.
Jiang F; Mao MY; Xiang Y; Lu X; Guan CL; Jiao LZ; Wan XR; Feng FZ; Ren T; Yang JJ; Zhao J
BMC Cancer; 2023 Aug; 23(1):784. PubMed ID: 37612621
[TBL] [Abstract][Full Text] [Related]
3. A prospective cohort study with serum anti-mullerian hormone levels change in patients undergoing uterine preservation after gestational trophoblastic neoplasia treatment with a methotrexate regimen.
Tuan Dat D; Huyen Thuong PT; Hong Hai D; Khac Toan N; Tai Duc N; Duy Anh N; Thi Thu Ha N
Clin Ter; 2024; 175(2):128-134. PubMed ID: 38571471
[TBL] [Abstract][Full Text] [Related]
4. First-line monodrug chemotherapy in low-risk gestational trophoblastic neoplasia: a network meta-analysis.
Zhou F; Kemin L
Front Oncol; 2023; 13():1276771. PubMed ID: 38250546
[TBL] [Abstract][Full Text] [Related]
5. The Effects of Chemotherapy on the Levels of Serum Anti-Müllerian Hormone in Patients with Gestational Trophoblastic Neoplasia.
Zamani M; Mohsenpour F; Torkzaban F; Atrvash N; Majlesi A; Torkzaban A
J Reprod Infertil; 2023; 24(1):43-48. PubMed ID: 36919051
[TBL] [Abstract][Full Text] [Related]
6. PREDICT-GTN 2: Two-factor streamlined models match FIGO performance in gestational trophoblastic neoplasia.
Parker VL; Winter MC; Tidy JA; Palmer JE; Sarwar N; Singh K; Aguiar X; Hancock BW; Pacey AA; Seckl MJ; Harrison RF
Gynecol Oncol; 2024 Jan; 180():152-159. PubMed ID: 38091775
[TBL] [Abstract][Full Text] [Related]
7. Gestational Trophoblastic Neoplasia-A Retrospective Analysis of Patients Treated at a Tertiary Care Oncology Center in North India.
Gupta A; Kapoor A; Mishra BK; Kashyap L; Choudhary A; Singh A; Singh N; Sansar B
South Asian J Cancer; 2023 Apr; 12(2):153-158. PubMed ID: 37969673
[TBL] [Abstract][Full Text] [Related]
8.
Porragas-Paseiro HS; Johnson S; Brubaker L; Sanders BE
Gynecol Oncol Rep; 2023 Dec; 50():101286. PubMed ID: 37860081
[TBL] [Abstract][Full Text] [Related]
9. Role of Salvage Surgery in Gestational Trophoblastic Neoplasia: a Regional Cancer Centre Experience.
Tejas SV; Pallavi VR; Shobha K; Rajshekhar SK
Indian J Surg Oncol; 2022 Dec; 13(4):702-706. PubMed ID: 36687227
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of 5-fluorouracil/cisplatin/vincristine as a multi-agent chemotherapy regimen in gestational trophoblastic neoplasia.
Wang L; Wang Q; Xu Z; Yang L; Wang W
Front Oncol; 2023; 13():1240972. PubMed ID: 38023226
[TBL] [Abstract][Full Text] [Related]
11. Severe methotrexate hypersensitivity during treatment for Gestational trophoblastic Neoplasia: Case Report and considerations for management.
Kar A; Mills KA
Gynecol Oncol Rep; 2024 Apr; 52():101364. PubMed ID: 38495802
[TBL] [Abstract][Full Text] [Related]
12. The 16-year experience in treating low-risk gestational trophoblastic neoplasia patients with failed primary methotrexate chemotherapy.
Wu X; Qin J; Shen T; Fei W; Chen L; Xie X; Lu W
J Gynecol Oncol; 2020 Jul; 31(4):e36. PubMed ID: 32026657
[TBL] [Abstract][Full Text] [Related]
13. Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia.
Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
Gynecol Oncol; 2009 Feb; 112(2):353-7. PubMed ID: 19059633
[TBL] [Abstract][Full Text] [Related]
14. Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jun; 117(3):477-80. PubMed ID: 20347479
[TBL] [Abstract][Full Text] [Related]
15. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy.
Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
J Reprod Med; 2010; 55(7-8):279-84. PubMed ID: 20795339
[TBL] [Abstract][Full Text] [Related]
16. Development of single-agent chemotherapy regimens for gestational trophoblastic disease.
Homesley HD
J Reprod Med; 1994 Mar; 39(3):185-92. PubMed ID: 7518517
[TBL] [Abstract][Full Text] [Related]
17. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia.
Lurain JR; Nejad B
Gynecol Oncol; 2005 May; 97(2):618-23. PubMed ID: 15863169
[TBL] [Abstract][Full Text] [Related]
18. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
Chen YX; Shen YM; Qian JH; Xie X
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
